A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis
NCT ID: NCT07173478
Last Updated: 2025-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE3
156 participants
INTERVENTIONAL
2025-10-31
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis
NCT07184645
A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects
NCT02334787
Study of OPA-15406 Ointment in Patients With Atopic Dermatitis
NCT02914548
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
NCT01702181
Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome
NCT03908970
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1% OPA-15406 foam
OPA-15406
1% foam, topical, twice daily, for 4 weeks
Vehicle
Vehicle
vehicle, topical, twice daily, for 4 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OPA-15406
1% foam, topical, twice daily, for 4 weeks
Vehicle
vehicle, topical, twice daily, for 4 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants with a history of AD for at least 3 years
* Participants who have an affected area covering from 5% to 40% of their body surface area (excluding the scalp) at the screening and baseline examinations
* Participants with an IGA score of 2 or 3 at the screening and baseline examinations
Exclusion Criteria
* Participants who have been treated with OPA-15406 ointment in the past
15 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Otsuka Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nobuhito Sanada
Role: STUDY_DIRECTOR
Otsuka Pharmaceutical Co., Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mita Dermatology Clinic
Tokyo, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Drug Information Center
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
271-102-00043
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.